Complement System
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
All Product Categories
-
Complement System Inhibitors
(135)
View all products
-
Complement System Agonists
(13)
View all products
-
Complement System Antagonists
(21)
View all products
-
Complement System Activators
(8)
View all products
-
Complement System Modulator
(1)
View all products
-
Complement System Controls
(2)
View all products
-
Complement System Ligands
(3)
View all products
-
Complement System Proteins
(113)
View all products
-
Complement System 관련 제품 (213)
관련 제품 (213)
-
Recombinant Proteins (113)
-
Antibodies (7)
-
Olendalizumab
0 ImagesCat. No.: HY-P99767CAS No.: 2210314-30-8Synonyms: ALXN1007; LendalizumabOlendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus.
-
ARC186 sodium
0 ImagesCat. No.: HY-153098AARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
-
SB290157 trifluoroacetate (Standard)
0 ImagesSB290157 (trifluoroacetate) (Standard) is the analytical standard of SB290157 (trifluoroacetate) (HY-101502A). This product is intended for research and analytical applications. SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
-
CP-289,503
0 ImagesCP-289,503 is an inhibitor of the complement C5a receptor with an IC50 of 1 μM. C5a acts as an activator of leukocytes and phagocytes during complement system activation. The C5a receptor can bind to C5a, which can stimulate the upregulation of cell surface integrins and degranulation of inflammatory cells, leading to endothelial cell damage. C5a receptor inhibitors can block C5a signaling and inhibit a variety of inflammatory diseases.
-
(Z)-Leukadherin-1
0 ImagesCat. No.: HY-15701ACAS No.: 2055362-72-4Synonyms: ADH-503 free base(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
-
Ebribafusp alfa
0 ImagesCat. No.: HY-P990955CAS No.: 2839652-75-2Synonyms: ADX-097Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis.
-
Compstatin control peptide
0 ImagesCompstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
-
CP-447697
0 ImagesCP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation.
-
Cyclosporin A-13C2,d4
0 ImagesCat. No.: HY-B0579S3Synonyms: Cyclosporine A-13C2,d4; Ciclosporin A-13C2,d4; CsA-13C2,d4Cyclosporin A-13C2,d4 (Cyclosporine A-13C2,d4) is the deuterated, 13C-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
-
Factor B-IN-1
0 ImagesCat. No.: HY-136556CAS No.: 1481631-75-7Factor B-IN-1 is a Factor B inhibitor extracted from patent WO2013164802A1, Example 24.
-
C3a (70-77)
0 ImagesCat. No.: HY-P1505CAS No.: 63555-63-5Synonyms: Complement 3a (70-77)C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
-
Pexelizumab
0 ImagesSynonyms: h5G1. 1-SCPexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
-
Cyclosporin A acetate-d4
0 ImagesCat. No.: HY-B0579S2Synonyms: Cyclosporine A acetate-d4; Ciclosporin A acetate-d4; CsA acetate-d4Cyclosporin A acetate-d4 (Cyclosporine A acetate-d4) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
-
Entadamide-A-β-D-glucopyranoside
0 ImagesEntadamide-A-β-D-glucopyranoside is one of the major components in the seeds of Entada phaseoloides. Entadamide-A-β-D-glucopyranoside has anti-complement activitie.
-
RPARPAR acetate
0 ImagesCat. No.: HY-P11647APurity: 99.47%RPARPAR acetate is a CendR tumor-penetrating peptide. RPARPAR acetate directly binds to the NRP-1 and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR acetate serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR acetate is applicable in research on tumor targeting and drug delivery.
-
Izastobart
0 ImagesSynonyms: HIB210; MOR044254; MOR210; TJ-210; TJ-210001; WBP2191Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
-
Greziprubart
0 ImagesCat. No.: HY-P990998CAS No.: 2894136-80-0
